Spots Global Cancer Trial Database for targeted therapy
Every month we try and update this database with for targeted therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | NCT06427798 | Somatostatin Re... Gastrointestina... Pheochromocytom... Paragangliomas | 68Ga-DOTATATE [203Pb]VMT-alph... [212Pb]VMT-alph... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer | NCT04211337 | Medullary Thyro... | Selpercatinib Cabozantinib Vandetanib | 12 Years - | Eli Lilly and Company | |
| BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors | NCT00095459 | Neoplasms | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Nimotuzumab Combined With Radiotherapy for Older Patients With Esophageal Cancer: a Single, Non-control Clinical Trial | NCT01463605 | Esophageal Canc... | Nimotuzumab | 70 Years - | ChineseAMS | |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT05358249 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Colorectal Canc... Colorectal Carc... Colorectal Neop... Colorectal Tumo... Neoplasms, Colo... | JDQ443 trametinib Ribociclib cetuximab | 18 Years - | Novartis | |
| Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | NCT02920996 | Carcinoma, Non-... Solid Tumor | Merestinib | 18 Years - | Dana-Farber Cancer Institute | |
| ANG1005 in Leptomeningeal Disease From Breast Cancer | NCT03613181 | Leptomeningeal ... Leptomeningeal ... Brain Metastase... HER2-negative B... | ANG1005 Physician's Bes... | 18 Years - | Angiochem Inc | |
| Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer | NCT05044871 | Ovarian Cancer | Pamiparib Bevacizumab Tislelizumab Nab paclitaxel Bevacizumab + N... | 18 Years - | Tongji Hospital | |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | NCT03452774 | Cancer, Metasta... Cancer Cancer of Pancr... Cancer of Liver Cancer of Stoma... Cancer Liver Cancer of Rectu... Cancer of Kidne... Cancer of Esoph... Cancer of Cervi... Cancer of Colon Cancer of Laryn... Cancer, Lung Cancer, Breast Cancer, Advance... Cancer Prostate Cancer of Neck Cancer of Skin Neuroendocrine ... Carcinoma Mismatch Repair... BRCA Gene Rearr... Non Hodgkin Lym... Leukemia Non Small Cell ... Cholangiocarcin... Glioblastoma Central Nervous... Melanoma Urothelial Carc... Bladder Cancer Ovarian Cancer Endometrial Can... Testicular Canc... Breast Cancer COVID Myelofibrosis Myeloproliferat... Myeloproliferat... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... | Clinical Trial ... | - | Massive Bio, Inc. | |
| Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC) | NCT05660213 | Unresectable He... | Huaier granule Atezolizumab + ... Camrelizumab+Ap... Sintilimab+Beva... | 18 Years - | Fudan University | |
| Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | NCT02795156 | Non-small Cell ... Urothelial Carc... Gastrointestina... Upper Aerodiges... | Afatinib Regorafenib Cabozantinib | 18 Years - | SCRI Development Innovations, LLC | |
| An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal | NCT05225844 | Gastrointestina... Immunotherapy Targeted Therap... | Camrelizumab Apatinib Mesyla... | 18 Years - 75 Years | Harbin Medical University | |
| Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma | NCT00761280 | Anaplastic Astr... Glioblastoma | trabedersen temozolomide Drug delivery s... Placement of Dr... carmustine lomustine | 18 Years - 70 Years | Isarna Therapeutics GmbH | |
| CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer | NCT00330746 | Advanced Non-Sm... | cetuximab gemcitabine gemcitabine cetuximab | 18 Years - | National Cancer Institute, Naples | |
| Research on Intelligent Screening and Decision-making for Neoadjuvant Therapy in Locally Advanced Gastric Cancer Based on Multi-omics Integration | NCT06396143 | Locally Advance... | 18 Years - 75 Years | Zhejiang University | ||
| Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma | NCT02401542 | Locally Advance... Urinary Bladder... Urological Dise... | Vofatamab Docetaxel Placebo | 18 Years - | Rainier Therapeutics | |
| Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients | NCT04222335 | Lung Cancer, No... | Blood samples | 18 Years - | University Hospital, Toulouse | |
| Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study | NCT01190241 | Advanced Solid ... Inoperable Metastasis | desatinib or su... | 18 Years - | Amsterdam UMC, location VUmc | |
| Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer | NCT00322400 | Locally Recurre... | Docetaxel Paclitaxel AMG 706 | 18 Years - | Amgen | |
| GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC) | NCT05003895 | Hepatocellular ... Hepatocellular ... Metastatic Hepa... | Cyclophosphamid... CAR-T cell Fludarabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC | NCT05163249 | Carcinoma, Non-... | Osimertinib Savolitinib | 18 Years - | Guangdong Association of Clinical Trials | |
| Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients | NCT06311981 | Non-small Cell ... Older People Carbon Ion Radi... Radiotherapy Si... | carbon ion radi... targeted therap... single regimen ... | 75 Years - | Shanghai Proton and Heavy Ion Center | |
| Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma | NCT04310397 | Pathologic Stag... Pathologic Stag... Pathologic Stag... | Dabrafenib Spartalizumab Therapeutic Con... Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma | NCT02889692 | Cancer | YiQiFang YangYinFang YiQiYangYinFang placebo granule... Erlotinib® Gefitinib® Icotinib® | 18 Years - | Shanghai University of Traditional Chinese Medicine | |
| Merestinib In Non-Small Cell Lung Cancer And Solid Tumors | NCT02920996 | Carcinoma, Non-... Solid Tumor | Merestinib | 18 Years - | Dana-Farber Cancer Institute | |
| A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a | NCT00117013 | Neoplasms | Fluorine-19-Flu... Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Primary Tumour Response to Induction Chemotherapy in Synchronously Metastasized Colorectal Cancer | NCT05172635 | Gastrointestina... | 18 Years - | Klinik Favoriten | ||
| Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence | NCT06228599 | Pancreas Cancer | Treatment Plan | 18 Years - | Medical College of Wisconsin | |
| N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy | NCT02142036 | Metastatic Canc... | EMA-approved AT... | 18 Years - | Oslo University Hospital | |
| Two Dose Schedules of Panitumumab in Subjects With Advanced Solid Tumors | NCT00091806 | Tumors Oncology Solid Tumors | panitumumab (AB... Panitumumab | 18 Years - | Amgen | |
| Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China | NCT03792529 | Breast Cancer | detect gene mut... | 18 Years - 80 Years | Peking University Cancer Hospital & Institute | |
| A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre | NCT05058937 | Solid Tumor Metastatic Canc... | Comprehensive g... | 18 Years - | The Belgian Society of Medical Oncology | |
| Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | NCT04480099 | Peripheral T-ce... | CHOP CHOP+X | 18 Years - | Ruijin Hospital | |
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma | NCT03436732 | Mesothelioma | LMB-100 SEL-110 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy | NCT03880617 | CML GIST | - | National Taiwan University Hospital | ||
| Histiocytic Disorder Follow-up Study | NCT05915208 | Histiocytosis Langerhans Cell... Erdheim-Chester... Rosai Dorfman D... Xanthogranuloma Malignant Histi... | 18 Years - 89 Years | University of Alabama at Birmingham | ||
| A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | NCT04913285 | Solid Tumor, Ad... Non-small Cell ... Melanoma | KIN-2787 KIN-2787 and bi... | 18 Years - | Pierre Fabre Medicament | |
| Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer | NCT01394120 | Carcinoma, Panc... | Targeted Therap... Standard Chemot... | 18 Years - | Grupo Hospital de Madrid | |
| GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L) | NCT01497665 | Non-small Cell ... | GRN1005 | 18 Years - | Angiochem Inc | |
| Systematic Evaluation of Human Explant Model Systems Engineering | NCT04671654 | Solid Tumor, Ad... | 18 Years - | University Hospital Heidelberg | ||
| Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | NCT01473095 | Solid Tumor Malignant Lymph... Tumor | ARQ 092 | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations | NCT05983159 | Slow-Flow Vascu... Fast-Flow Vascu... Vascular Malfor... Venous Malforma... Lymphatic Malfo... Lymphatic Malfo... Lymphangioma Arteriovenous M... Venous Malforma... Cystic Hygroma Vascular Anomal... Vascular Anomal... PI3K Gene Mutat... MAP2K1 Gene Mut... PIK3CA-related ... Arteriovenous M... KRAS G12C KRAS G12D | Alpelisib Mirdametinib | 2 Years - | Murdoch Childrens Research Institute | |
| Evaluating the CAREchart@Home™ Program for Enhancing After-hours Cancer Care | NCT04232709 | Cancer | Shared electron... | 18 Years - 100 Years | Women's College Hospital | |
| Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy | NCT06427798 | Somatostatin Re... Gastrointestina... Pheochromocytom... Paragangliomas | 68Ga-DOTATATE [203Pb]VMT-alph... [212Pb]VMT-alph... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Chemical and Genetic Effects of the Experimental Anti-Cancer Drugs in Cheek Cells in Cancer Patients | NCT00055380 | Cancer | Oral cytobrushi... | - | National Institutes of Health Clinical Center (CC) | |
| Donafenib for Recurrent Cervical Cancer | NCT05310331 | Targeted Therap... Chemotherapy Recurrent Cervi... Metastatic Cerv... Persistent Adva... Survival Outcom... Adverse Effect | Donafenib combi... | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases | NCT01480583 | Breast Cancer Brain Metastase... | GRN1005 Trastuzumab 18F-FLT | 18 Years - | Angiochem Inc | |
| (COVID-19) Longitudinal Neutralizing Antibody Titers in Cancer Patients Receiving Different Anti-caner Therapies | NCT05384509 | Cancer | solid organ mal... | 20 Years - | Chang Gung Memorial Hospital | |
| SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma | NCT01445392 | Mesothelioma | Multicycle SS1P Pemetrexed Cisplatin Single cycle SS... | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies | NCT02504346 | Lung Cancer Targeted Therap... | AZD9291 | 18 Years - | Oslo University Hospital | |
| Maitake for Integrative Cancer Care | NCT06323473 | Cancer | Black Maitake P... | 18 Years - | The Canadian College of Naturopathic Medicine | |
| Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer | NCT02132884 | Malignant Peric... Malignant Pleur... Recurrent Non-s... Stage IIIB Non-... Stage IV Non-sm... | cytology specim... therapeutic pro... targeted therap... laboratory biom... | - | Fox Chase Cancer Center | |
| KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | NCT04265534 | Non-Small Cell ... Non-squamous No... Non-Squamous No... KEAP1 Gene Muta... NRF2 Gene Mutat... NFE2L2 Gene Mut... | Telaglenastat Carboplatin Che... Pemetrexed Chem... Pembrolizumab I... Placebo Folic acid 400 ... Vitamin B12 100... Dexamethasone 4... | 18 Years - | Calithera Biosciences, Inc | |
| PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc | NCT04814095 | Cancer | QOL CT imaging | 18 Years - | British Columbia Cancer Agency | |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | NCT04194944 | Non-Small Cell ... | Selpercatinib Carboplatin Cisplatin Pemetrexed Pembrolizumab | 18 Years - | Eli Lilly and Company | |
| HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma | NCT05489692 | Intrahepatic Ch... | hepatic arteria... | 18 Years - | Sun Yat-sen University | |
| ANG1005 in Leptomeningeal Disease From Breast Cancer | NCT03613181 | Leptomeningeal ... Leptomeningeal ... Brain Metastase... HER2-negative B... | ANG1005 Physician's Bes... | 18 Years - | Angiochem Inc | |
| A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a | NCT00117013 | Neoplasms | Fluorine-19-Flu... Topotecan | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Molecular Analysis and Treatment Options of Thymic Malignancies | NCT05667948 | Thymic Epitheli... Thymic Carcinom... Thymic Cancer | Chemotherapy | 18 Years - | Shanghai Chest Hospital | |
| Chronic Myeloid Leukemia (CML) Real-Life Database | NCT05963061 | Chronic Myeloid... | - | University Hospital, Clermont-Ferrand | ||
| Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma | NCT05816642 | Metastatic Rena... | sunitinib or pa... PD-1 inhibitor ... | - | RenJi Hospital | |
| Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia | NCT05350826 | Chronic Lymphoi... | Ambulatory medi... | 18 Years - | University Hospital, Toulouse | |
| a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors | NCT05177666 | Feasibility Effectiveness Safety Targeted Molecu... | Targeted therap... | 18 Years - | The University of Hong Kong-Shenzhen Hospital | |
| Derazantinib and Atezolizumab in Patients With Urothelial Cancer | NCT04045613 | Urothelial Carc... | Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 30... Derazantinib 20... | 18 Years - | Basilea Pharmaceutica | |
| Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | NCT04705129 | Primary Mediast... EBV-Positive DL... | Zanubrutinib Tislelizumab | 18 Years - 80 Years | Ruijin Hospital | |
| Personalized Medicine for Advanced Biliary Cancer Patients | NCT05615818 | Biliary Tract N... | Futibatinib Ivosidenib Zanidatamab Trastuzumab Neratinib Encorafenib Binimetinib Niraparib Cisplatin Gemcitabine | 18 Years - | UNICANCER | |
| MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma | NCT01333475 | Colorectal Neop... | MK-2206 + AZD62... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Systematic and Mechanism-based Approach to Rational Treatment Trials of Blood Cancer | NCT03488641 | Hematologic Dis... Treatment | ex-vivo drug re... | 18 Years - | German Cancer Research Center | |
| A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations | NCT01131429 | Neoplasms, Lung Carcinoma, Non-... Drug Therapy Genes, EGFR | Erlotinib Docetaxel Cisplatin Docetaxel Cisplatin Erlotinib | 18 Years - | Chinese PLA General Hospital | |
| Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung Cancer | NCT02671045 | Carcinoma, Non-... | Genomic profile... Genomic profile... | 18 Years - | Cota Inc. | |
| HRQOL in Locally Advanced Thyroid Carcinoma | NCT05824312 | Thyroid Cancer Tyrosine Kinase... Health Related ... | Tyrosine kinase... | 18 Years - 70 Years | Fujian Cancer Hospital | |
| Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy | NCT03880617 | CML GIST | - | National Taiwan University Hospital | ||
| EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide | NCT00132522 | Ovarian Cancer Colorectal Canc... Carcinoma, Non-... Prostate Cancer | EMD 273066 | 18 Years - | EMD Serono | |
| Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression. | NCT00408967 | Ovarian Cancer | Tucotuzumab cel... | 18 Years - | EMD Serono | |
| A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients | NCT03145961 | Triple Negative... | Pembrolizumab | 16 Years - | Institute of Cancer Research, United Kingdom | |
| Exploratory Drug Interaction Study Between SMIs and DOACs | NCT05732350 | Solid Tumor Cancer, Lung | 18 Years - | Maastricht University Medical Center | ||
| Multicenter Tissue Registry in Melanoma | NCT05750511 | Metastatic Mela... | molecular tissu... | 18 Years - | Dermatologic Cooperative Oncology Group | |
| First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer | NCT03804580 | Lung Cancer | osimertinib | 18 Years - | Vestre Viken Hospital Trust | |
| Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer | NCT00140556 | Head and Neck C... Pharynx Cancer | Chemoradiothera... Cisplatin Bevacizumab Erlotinib | 18 Years - | Duke University | |
| Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell Carcinoma | NCT05188118 | Renal Cell Carc... | Cabozantinib Ipilimumab Nivolumab Lenvatinib Everolimus | 18 Years - 99 Years | Icahn School of Medicine at Mount Sinai |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
